Text and Data Mining valid from 2019-08-22
First Online: 22 August 2019
Compliance with Ethical Standards
: No sources of funding were received for the preparation of this article or conduct of this study.
: PC, CHTY, JL, CA, YSP, TW, HT and AI declared they had no conflict of interest or that their conflict of interest was not relevant to this publication. SEC has served as a consultant for Shire. VB served on the Speakers bureau for Shire. SB has received grants from Baxalta and Takeda for studies about PK-tailored therapy in patients with severe hemophilia A using a specific tool (myPKFiT), has lectured and has been part of medical and commercial advisory boards organized by Takeda and Baxalta in the past, and has chaired meetings about rurioctocog. JEMV has received research support from Shire and Grifols and speaker, support consulting fees from Bayer, CSL Behring, Grifols, NovoNordisk, Pfizer, Shire, Sobi, Takeda. AN received honoraria from Shire/Baxalta, Bioverative, Bayer and Chugai. FCM served on Octapharma, Shire, Kendrion, Genentech advisory boards. AS served on Shire, Biogen and CSL Behring advisory boards. MC received honoraria from NovoNordisk, Shire, Genentech, Baxalta, Bayer, BPL, Octapharma. ANE has received speaking fees from Bayer.